Leo Cui
General Partner at FoundersX Ventures
Cambridge, Massachusetts
Overview
Work Experience
General Partner | Deep-tech and AI investments
2022 - Current
FoundersX Ventures is a cross stage venture capital firm based in Silicon Valley. Our investments have strong focus on game-changing technologies in high growth industries, including quantum computing, enterprise SaaS, Fintech, biotech, telehealth, and low-carbon solutions. We are strategic investors, adding values in bringing in global capital and enterprise partners, and access to top engineering talent in Stanford, Berkeley, Harvard and MIT. Our investment team is highly engaging and operation driven. We enjoy empowering daring tech founders to change the world!
Venture Capital Fellow | Deep-tech venture
2020 - 2022
Advisory Council
2024
Help chart Harvard Business Review’s future direction!
Investor
2023
We use AI to help you write patents. We do this by providing a simple in-browser document editor that any patent attorney or inventor can start using straight away. Our product can help with all stages of the patent life cycle, from drafting and filing to prosecution and opposition. If you are an an inventor, a patent attorney, or even just an enthusiast interested in the intersection of AI and intellectual property, we would love to hear from you: https://www.solveintelligence.com/contact-us
Investor
2022
Our mission is to make AI radically cheaper. We are the world leaders in algorithm/hardware co-design for artificial intelligence. Our roadmap begins with products 100x better than GPUs and will ultimately deliver products that are many orders of magnitude more cost effective than what is available today. We will ultimately be able to put models the size of ChatGPT into chips the size of a thumbnail.
Rain AI develops an energy-efficient hardware for artificial intelligence (AI) applications.
Raised $40,230,020.00 from Epic Venture Partners, Loup Ventures, George Godula, Pioneer Fund, Driving Forces, Guillaume Glaunès, Prosperity7 Ventures, Team Ignite Ventures and Buckley Ventures.
Investor
2023
TechBio company decoding the immune system in high resolution to inform therapy and develop diagnostics through the convergence of immune cell sequencing and artificial intelligence. We bring together bright minds from multiple disciplines. We are driven to shorten the timeline from research to real-world human impact. Our motivation is to put science in service of humanity.
Building the world's largest immune databank.
Raised $8,616,105.00 from Horizon Europe, Medical Research Future Fund (MRFF), Horizon Europe, European Commission and Malta Enterprise.
Investor
2023
We are a lifesciences products company specializing in building tools and generating insights at the interface of biology, chemistry and engineering. We work extensively in cellular analysis and in understanding how genetic code becomes functional output.
Zafrens offers a throughput platform for cell characterization, correlating molecular profiles to phenotype for accelerated drug discovery.
Raised $29,000,000.00 from Prime Movers Lab, BlueYard Capital, Global Brain Corporation, Iaso Ventures, Alix Ventures, KOFA Healthcare, Possible Ventures, Hawktail Management and FoundersX Ventures.
Investor
2022
Building a sustainable future in space. Building spacecraft for space situational awareness and in space logistics.
Turion Space provides space domain awareness data and space logistic services.
Raised $27,825,000.00 from Veteran Ventures Capital.
Investor
2024
We sequence proteins. Glyphic Biotechnologies is a biotechnology startup revolutionizing the field of proteomics. While DNA can reveal biological insights, proteins actually tell us what our bodies will do. We are developing a first-of-its-kind, next-generation protein sequencing platform to enable researchers to gain novel insights into biology and disease.
Glyphic Biotechnologies is a biotechnology company that develops a protein sequencing platform.
Raised $7,783,799.00 from stealth.vc.
Investor
2024
Arintra’s medical coding software offers two powerful modes for medical coding: autonomous coding mode and assisted coding mode. In autonomous coding mode, direct-to-billing claims are generated autonomously with high accuracy, streamlining the billing process for healthcare provider organizations. Whereas, assisted coding mode allows medical coders to meticulously review and optimize charges before submission, leading to increased efficiency and precision in the coding process. With Arintra, healthcare provider organizations can rely on precise direct-to-billing claims that include essential codes like E/M levels, CPT, ICD-10, HCC, HCPCS with appropriate modifiers and units. Arintra’s coding solution provides extensive coverage and flexibility, catering to various coding domains such as professional coding, professional-fee coding, facility coding, and inpatient coding.
Arintra is a software development company for health care.
Raised $190,000.00 from TEN13 and NetApp Excellerator.
Investor
2022
Breakthrough medical device company for AD, Dementia, PD and other neural disorders. MIT Spin-off. Raised $70M at B round with remarkable phase II human trial data. Currently in Phase 3 trial.
Cognito Therapeutics San Francisco is a neurotechnology company that is developing disease-modifying treatments for CNS illnesses.